159 related articles for article (PubMed ID: 19202599)
1. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.
Weissman AM; Yang Y; Kitagaki J; Sasiela CA; Beutler JA; O'Keefe BR
Ernst Schering Found Symp Proc; 2008; (1):171-90. PubMed ID: 19202599
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.
Clement JA; Kitagaki J; Yang Y; Saucedo CJ; O'Keefe BR; Weissman AM; McKee TC; McMahon JB
Bioorg Med Chem; 2008 Dec; 16(23):10022-8. PubMed ID: 18977148
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.
Kitagaki J; Agama KK; Pommier Y; Yang Y; Weissman AM
Mol Cancer Ther; 2008 Aug; 7(8):2445-54. PubMed ID: 18723490
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
Auger KR; Copeland RA; Lai Z
Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
7. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
[TBL] [Abstract][Full Text] [Related]
8. Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53.
Kitagaki J; Yang Y; Saavedra JE; Colburn NH; Keefer LK; Perantoni AO
Oncogene; 2009 Jan; 28(4):619-24. PubMed ID: 18978812
[TBL] [Abstract][Full Text] [Related]
9. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
Dickens MP; Roxburgh P; Hock A; Mezna M; Kellam B; Vousden KH; Fischer PM
Bioorg Med Chem; 2013 Nov; 21(22):6868-77. PubMed ID: 24113239
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-protein ligase activity of Hdm2 is inhibited by nucleic acids.
Linares LK; Scheffner M
FEBS Lett; 2003 Nov; 554(1-2):73-6. PubMed ID: 14596917
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of novel ubiquitin-activating enzyme inhibitors.
Itoh Y; Suzuki M
Bioorg Med Chem Lett; 2018 Sep; 28(16):2723-2727. PubMed ID: 29548576
[TBL] [Abstract][Full Text] [Related]
13. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.
Kostic M; Matt T; Martinez-Yamout MA; Dyson HJ; Wright PE
J Mol Biol; 2006 Oct; 363(2):433-50. PubMed ID: 16965791
[TBL] [Abstract][Full Text] [Related]
14. Targeting E3 ubiquitin ligases for cancer therapy.
Sun Y
Cancer Biol Ther; 2003; 2(6):623-9. PubMed ID: 14688465
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the p53/hDM2 protein-protein interaction by cyclometallated iridium(III) compounds.
Liu LJ; He B; Miles JA; Wang W; Mao Z; Che WI; Lu JJ; Chen XP; Wilson AJ; Ma DL; Leung CH
Oncotarget; 2016 Mar; 7(12):13965-75. PubMed ID: 26883110
[TBL] [Abstract][Full Text] [Related]
16. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
17. From Discovery to Bedside: Targeting the Ubiquitin System.
Wertz IE; Wang X
Cell Chem Biol; 2019 Feb; 26(2):156-177. PubMed ID: 30554913
[TBL] [Abstract][Full Text] [Related]
18. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26.
Zhang Y; Wang J; Yuan Y; Zhang W; Guan W; Wu Z; Jin C; Chen H; Zhang L; Yang X; He F
Nucleic Acids Res; 2010 Oct; 38(19):6544-54. PubMed ID: 20542919
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of ubiquitin-activating enzyme (E1), a new class of potential cancer therapeutics.
Yang Y; Kitagaki J; Dai RM; Tsai YC; Lorick KL; Ludwig RL; Pierre SA; Jensen JP; Davydov IV; Oberoi P; Li CC; Kenten JH; Beutler JA; Vousden KH; Weissman AM
Cancer Res; 2007 Oct; 67(19):9472-81. PubMed ID: 17909057
[TBL] [Abstract][Full Text] [Related]
20. MDM2 inhibition: an important step forward in cancer therapy.
Konopleva M; Martinelli G; Daver N; Papayannidis C; Wei A; Higgins B; Ott M; Mascarenhas J; Andreeff M
Leukemia; 2020 Nov; 34(11):2858-2874. PubMed ID: 32651541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
